

Malaysian Genomics to Offer World's First DNA-Driven Fertility Test

Group in strategic collaboration with Divine Genes to offer genetic tests related to reproductive health in Malaysia and overseas

PETALING JAYA, 22 February 2023 – **Malaysian Genomics Resource Centre Berhad** (“Malaysian Genomics” or “the Group”), a leading genomics and biopharmaceutical specialist, today announced that the Group has signed a strategic collaboration agreement with Divine Genes Sdn Bhd (“Divine Genes”) to collaborate on business opportunities in relation to the improvement and international distribution of genetic tests for reproductive health.

Divine Genes is an investment holding company with businesses in pharmaceutical product distribution, financial consultancy services as well as general merchandise and trading.

Under the strategic collaboration, Divine Genes’ genetic test for reproductive health will be added to Malaysian Genomics’ genetic test portfolio, which will market and distribute these tests in Malaysia and overseas. Both parties will also cooperate in improving the product.



Sasha Nordin, Chief Executive Officer of Malaysian Genomics ([Link](#))

En. Sasha Nordin, Chief Executive Officer of Malaysian Genomics said, “Decreasing fertility and birth rates are common across the world, and demand for reproductive medicine is growing in many countries. This new, pioneering DNA-driven fertility test can help reproductive health specialists and their patients make important decisions in support of improving the outcome of fertility treatments. This test will form a critical part of Malaysian Genomics’ genetic screening portfolio of over 550 tests available across Southeast Asia and the Middle East where we have a presence.”

Dr. Pawel Suwinski of Divine Genes said, “This is a good opportunity for us to work with an organisation with the market reach, track record and platform to distribute our test. This collaboration is a good platform for both parties to leverage on each other’s strengths in improving the product and expanding the market for the test.”

###

ABOUT MALAYSIAN GENOMICS RESOURCE CENTRE BERHAD

Malaysian Genomics Resource Centre Berhad (“MGRC” or “the Group”) is a leading genomics and biopharmaceutical company based in Southeast Asia. The Group was established in 2004 and listed on the Bursa Malaysia stock exchange in 2010. From pioneering work in genome sequencing, bioinformatics analysis, and genetic screening services, MGRC has expanded into the biopharmaceutical sector with the manufacturing of cell therapies including immunotherapy for various types of cancer.

Utilising its high-throughput sequencing lab, advanced microarray facility, and new state-of-the-art cell processing lab, the Group is committed to improving access to the latest in precision and personalised healthcare solutions to improve the lives of patients.

For more information, visit www.mgrc.com.my.

Issued By: Swan Consultancy Sdn. Bhd. on behalf of Malaysian Genomics Resource Centre Berhad

Date: 22 February 2023

For more information, please contact:

Jazzmin Wan

Tel: +60 17-289 4110

Email: j.wan@swanconsultancy.biz

Amida Baharim

Tel: +60 12-206 1209

Email: a.baharim@swanconsultancy.biz
